| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
32,633,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
1,434,166 |
Avg
Vol: |
650,831 |
| 52
Week Range: |
$21.74 - $21.74 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  D Ambra Constance M |
10% Owner |
– – • |
2012-09-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500,000 |
3,078,768 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2012-09-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,500,000 |
3,125,434 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-08-24 |
4 |
S |
$3.22 |
$3,220 |
D/D |
(1,000) |
28,242 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2012-08-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,800 |
4,625,434 |
|
- |
|
| D Ambra Constance M |
10% Owner |
– – • |
2012-08-09 |
4 |
GD |
$0.00 |
$0 |
D/D |
25,800 |
4,578,768 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-08-09 |
4 |
S |
$3.00 |
$9,000 |
D/D |
(3,000) |
29,242 |
|
- |
|
| Roth Arthur J |
Director |
– • – |
2012-06-06 |
4 |
A |
$2.41 |
$17,499 |
D/D |
7,261 |
27,261 |
|
- |
|
| Oconnor Kevin |
Director |
– • – |
2012-06-06 |
4 |
A |
$2.41 |
$15,000 |
D/D |
6,224 |
24,577 |
|
- |
|
| Leung Gabriel |
Director |
– • – |
2012-06-06 |
4 |
A |
$2.41 |
$15,000 |
D/D |
6,224 |
19,478 |
|
- |
|
| Ryan Una S |
Director |
– • – |
2012-06-06 |
4 |
A |
$2.41 |
$15,000 |
D/D |
6,224 |
20,241 |
|
- |
|
| Marth William S |
Director |
– • – |
2012-06-06 |
4 |
A |
$2.41 |
$30,000 |
D/D |
12,448 |
12,448 |
|
- |
|
| Jordan Veronica Gh |
Director |
– • – |
2012-06-06 |
4 |
A |
$2.41 |
$15,000 |
D/D |
6,224 |
23,304 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-06-05 |
4 |
S |
$2.28 |
$1,149 |
D/D |
(504) |
33,492 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2012-06-05 |
4 |
S |
$2.28 |
$1,149 |
D/D |
(504) |
52,012 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2012-06-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,250) |
50,762 |
|
- |
|
| Henderson Lori M |
VP, general counsel |
• – – |
2012-06-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,458) |
37,774 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-06-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,250) |
32,242 |
|
- |
|
| Frost Mark T |
Chief Financial Officer |
• – – |
2012-06-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,667) |
74,599 |
|
- |
|
| D Ambra Thomas E Phd |
Chairman, CEO & President |
• • • |
2012-06-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,666) |
4,651,234 |
|
- |
|
| Ryan Una S |
Director |
– • – |
2012-05-22 |
4 |
B |
$2.81 |
$562 |
D/D |
200 |
14,017 |
2.31 |
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-05-15 |
4 |
S |
$3.01 |
$7,224 |
D/D |
(2,400) |
33,996 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-03-19 |
4 |
S |
$2.75 |
$2,975 |
D/D |
(1,078) |
36,396 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2012-03-19 |
4 |
S |
$2.75 |
$3,204 |
D/D |
(1,160) |
52,516 |
|
- |
|
| Hagen Steven R |
VP Pharmaceutical Dev & Mfg |
• – – |
2012-03-06 |
4 |
S |
$2.66 |
$242 |
D/D |
(91) |
37,474 |
|
- |
|
| Sargent Bruce J |
Sr VP, Drug Discovery |
• – – |
2012-03-06 |
4 |
S |
$2.66 |
$585 |
D/D |
(220) |
53,676 |
|
- |
|
620 Records found
|
|
Page 17 of 25 |
|
|
